(NASDAQ: OGI) Organigram Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Organigram Holdings's revenue in 2024 is N/A.On average, 5 Wall Street analysts forecast OGI's revenue for 2024 to be $9,947,169,373, with the lowest OGI revenue forecast at $8,946,446,475, and the highest OGI revenue forecast at $10,352,165,907. On average, 5 Wall Street analysts forecast OGI's revenue for 2024 to be $9,973,952,711, with the lowest OGI revenue forecast at $9,483,736,466, and the highest OGI revenue forecast at $10,352,165,907.
In 2025, OGI is forecast to generate $11,812,669,438 in revenue, with the lowest revenue forecast at $9,811,629,451 and the highest revenue forecast at $13,519,092,709.